JP2006504723A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504723A5
JP2006504723A5 JP2004542620A JP2004542620A JP2006504723A5 JP 2006504723 A5 JP2006504723 A5 JP 2006504723A5 JP 2004542620 A JP2004542620 A JP 2004542620A JP 2004542620 A JP2004542620 A JP 2004542620A JP 2006504723 A5 JP2006504723 A5 JP 2006504723A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
gemcitabine
acceptable salt
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004542620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504723A (ja
JP5416328B2 (ja
Filing date
Publication date
Priority claimed from GBGB0223380.7A external-priority patent/GB0223380D0/en
Application filed filed Critical
Publication of JP2006504723A publication Critical patent/JP2006504723A/ja
Publication of JP2006504723A5 publication Critical patent/JP2006504723A5/ja
Application granted granted Critical
Publication of JP5416328B2 publication Critical patent/JP5416328B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004542620A 2002-10-09 2003-10-06 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 Expired - Fee Related JP5416328B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0223380.7 2002-10-09
GBGB0223380.7A GB0223380D0 (en) 2002-10-09 2002-10-09 Combination therapy
PCT/GB2003/004334 WO2004032937A1 (en) 2002-10-09 2003-10-06 Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010287659A Division JP2011088921A (ja) 2002-10-09 2010-12-24 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用

Publications (3)

Publication Number Publication Date
JP2006504723A JP2006504723A (ja) 2006-02-09
JP2006504723A5 true JP2006504723A5 (enExample) 2006-11-24
JP5416328B2 JP5416328B2 (ja) 2014-02-12

Family

ID=9945538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004542620A Expired - Fee Related JP5416328B2 (ja) 2002-10-09 2003-10-06 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用
JP2010287659A Pending JP2011088921A (ja) 2002-10-09 2010-12-24 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010287659A Pending JP2011088921A (ja) 2002-10-09 2010-12-24 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用

Country Status (22)

Country Link
US (2) US20060009418A1 (enExample)
EP (1) EP1551409B1 (enExample)
JP (2) JP5416328B2 (enExample)
KR (1) KR101098061B1 (enExample)
CN (1) CN100363004C (enExample)
AT (1) ATE357236T1 (enExample)
AU (1) AU2003269253B2 (enExample)
BR (1) BR0315088A (enExample)
CA (1) CA2501651C (enExample)
CY (1) CY1106601T1 (enExample)
DE (1) DE60312715T2 (enExample)
DK (1) DK1551409T3 (enExample)
ES (1) ES2282656T3 (enExample)
GB (1) GB0223380D0 (enExample)
IL (1) IL167633A (enExample)
MX (1) MXPA05003595A (enExample)
NO (1) NO330601B1 (enExample)
NZ (1) NZ538999A (enExample)
PT (1) PT1551409E (enExample)
SI (1) SI1551409T1 (enExample)
WO (1) WO2004032937A1 (enExample)
ZA (1) ZA200502753B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU779695B2 (en) 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
DK1474420T3 (da) 2002-02-01 2012-05-21 Astrazeneca Ab Quinazolinforbindelser
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
ATE506062T1 (de) * 2003-02-13 2011-05-15 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
BRPI0612397A2 (pt) * 2005-07-06 2011-02-22 Astrazeneca Ab uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PT1971338E (pt) * 2005-12-22 2011-05-09 Astrazeneca Ab Combina??o de zd6474 e pemetrexed
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
CN101616671A (zh) 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
CN106619688A (zh) * 2016-12-27 2017-05-10 郑州郑先医药科技有限公司 一种治疗糖尿病的药物组合物及应用
CN106727657A (zh) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 一种治疗糖尿病的西药组合物及应用
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
PL203782B1 (pl) * 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6953679B2 (en) * 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
WO2004014383A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
ATE506062T1 (de) * 2003-02-13 2011-05-15 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
BRPI0612397A2 (pt) * 2005-07-06 2011-02-22 Astrazeneca Ab uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
PT1971338E (pt) * 2005-12-22 2011-05-09 Astrazeneca Ab Combina??o de zd6474 e pemetrexed
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
US20100212978A1 (en) * 2009-02-23 2010-08-26 Wen-Hung Huang Bicycle with two operation molds

Similar Documents

Publication Publication Date Title
JP2006504723A5 (enExample)
JP2005511597A5 (enExample)
JP2006500346A5 (enExample)
CA2501651A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
CA2531862A1 (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
JP2008514577A5 (enExample)
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
JP2005530735A5 (enExample)
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
WO2006035204A3 (en) Combination comprising zd6474 and an imatinib
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
WO2004071397A3 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
CA2531620A1 (en) Cancer combination therapy comprising azd2171 and zd1839
NO20064755L (no) Kombinasjonsterapi
JP2011500650A5 (enExample)
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine
ATE429435T1 (de) 7h-pyrrolopyrimidinderivate
JP2007538066A5 (enExample)
DE60308403D1 (de) Kombinationstherapie mit gemzitabin und zd6126